Anagliptin (INN; trade name Suiny) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It is approved for use in Japan. It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".
via PubMed
Anagliptin (INN; trade name Suiny) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It is approved for use in Japan. It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".
== Research == A systematic review and meta-analysis of anagliptin, published in 2024, found that it is effective in lowering blood glucose in people with type2 diabetes and that it may lower cholesterol.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).